PhaseV Launches AI to Automate Clinical Trials From Start to Submission

BOSTON, MA – March 17, 2026 – The notoriously complex, costly, and time-consuming process of bringing a new drug to market may be facing its most significant transformation yet. Boston-based PhaseV, a company specializing in artificial intelligence for clinical development, today announced the launch of its AI Conductor platform. The new solution aims to automate and unify the entire clinical trial journey, from the initial drafting of a study protocol to the final generation of submission-ready data for regulatory bodies like the FDA.

For decades, the clinical trial process has been a fragmented series of manual tasks, siloed departments, and endless document revisions, often leading to delays, inconsistencies, and staggering costs. PhaseV's AI Conductor promises to replace this disjointed workflow with a centralized, intelligent, and automated system designed to ensure speed, accuracy, and compliance from day one.

"AI Conductor transforms clinical development from a series of disconnected manual tasks into a synchronized, intelligent process," said Raviv Pryluk, PhD, CEO and Co-founder of PhaseV, in a statement. "Our AI doesn't work in isolation. It draws from a wide knowledge base to deliver insights, enforce document consistency across the full trial, and ensure every study is submission-ready from the start."

A Single Source of Truth for Drug Development

The core innovation of the AI Conductor is its function as an enterprise-grade workspace that serves as a single source of truth for the myriad teams involved in a clinical trial—from clinicians and data managers to statisticians and regulatory affairs specialists. Traditionally, designing a trial involves a high-stakes game of telephone, with information passed through countless emails, meetings, and document versions. This often results in misalignment between the study protocol, the statistical analysis plan, and the case report forms used to collect patient data.

PhaseV's platform tackles this by using generative AI to actively draft and connect these critical documents. It provides a shared, collaborative space where teams can work concurrently. The system offers real-time optimizations and suggestions grounded in regulatory logic, drawing from a connected knowledge base of a company's internal standard operating procedures (SOPs), historical trial documents, and industry templates. Features like granular permissions, inline commenting, and clear version histories are designed to enhance collaboration while maintaining a fully auditable trail of every decision and change—a critical requirement in the highly regulated pharmaceutical industry.

This approach aims to shift the paradigm from reactive problem-solving to proactive, AI-assisted design, empowering human experts to focus on high-level strategy and scientific insights rather than getting bogged down in administrative and repetitive tasks.

Automating the Complex Language of Regulatory Submission

A significant bottleneck in drug development lies in data management and the preparation of the final submission package. Regulatory agencies have strict requirements for data formatting and analysis to ensure consistency and reviewability. PhaseV's AI Conductor directly addresses this challenge by automating the creation of these complex components.

The platform integrates with data collection systems and automates the process of standardizing clinical data into required industry formats, such as the Study Data Tabulation Model (SDTM) and the Analysis Data Model (ADaM). This is a crucial and labor-intensive step that is prone to human error.

Furthermore, the system is designed to generate the statistical code needed to produce publication-ready Tables, Listings, and Figures (TLFs) and the comprehensive Clinical Study Report (CSR) that forms the backbone of an FDA submission. By ensuring the Statistical Analysis Plan (SAP) aligns with international guidelines like ICH E9 and that Case Report Forms (CRFs) are compliant with CDASH standards from the outset, the platform is engineered to prevent downstream errors and de-risk the final regulatory filing.

While the market for clinical trial management software (CTMS) includes established giants like Veeva and Medidata, PhaseV is positioning AI Conductor as a next-generation, end-to-end solution. Its key differentiator appears to be the deep integration of generative AI not just for workflow management, but for the actual creation of regulatory-compliant documents and code, promising a more holistic and seamless automation experience.

Navigating the Future of AI in a Regulated World

The launch comes at a time when regulatory bodies are actively defining the guardrails for AI in drug development. The FDA recently issued draft guidance on the use of AI/ML, emphasizing the need for transparency, validation, and a clear understanding of how models are trained and used. The European Union’s AI Act and data privacy laws like GDPR and HIPAA add further layers of complexity.

PhaseV appears to be building its platform with these constraints in mind. The company highlights its ISO 27001 certification and its compliance with GDPR and HIPAA, signaling a strong focus on data security and privacy. By grounding the AI's logic in a sponsor's own validated SOPs and historical data, the platform aims to create a transparent and defensible process for its AI-generated outputs.

While AI Conductor is a new offering, PhaseV has already established a track record with its suite of AI-powered "Optimizers," which help sponsors with trial design, site selection, and identifying patient subgroups. The company claims its solutions have already delivered significant returns for over 45 pharma and biotech sponsors, including reducing trial costs by up to 50% and increasing the probability of success by over 30%. This history of delivering tangible ROI with other AI tools lends credibility to the ambitious promises being made for its new, all-encompassing platform. By automating the intricate and arduous path to submission, PhaseV is betting that AI Conductor will become an indispensable tool for accelerating the delivery of new medicines to the patients who need them.